Document is current
Any future updates will be listed below
-
Authors
Revelas, Mary https://orcid.org/0000-0002-5249-022X
Thalamuthu, Anbupalam
Zettergren, Anna
Oldmeadow, Christopher
Najar, Jenna
Seidu, Nazib M.
Armstrong, Nicola J.
Riveros, Carlos
Kwok, John B.
Schofield, Peter R.
Trollor, Julian N.
Waern, Margda
Wright, Margaret J.
Zetterberg, Henrik
Ames, David
Belnnow, Kaj
Brodaty, Henry
Scott, Rodney J.
Skoog, Ingmar
Attia, John R.
Sachdev, Perminder S.
Mather, Karen A.
- License Information
-
More Information
Article History
Received: 7 April 2022
Accepted: 8 August 2022
First Online: 16 August 2022
Declarations
:
: HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, all unrelated to the work presented in this paper. All other authors declare no competing interests.
